Inhibitor Therapeutics, Inc.
Inhibitor Therapeutics, Inc. is a U.S.-based pharmaceutical development company focused on repurposing approved drugs into patent-protected cancer therapies. Its current lead effort centers on itraconazole-based treatments for basal cell carcinoma nevus syndrome (BCCNS), with additional programs referenced for prostate and lung cancers.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaDevelopment of itraconazole-based therapies for BCCNS and related basal cell carcinoma indications.
Early-stage development work for prostate cancer and lung cancer using the same repurposing platform.
Novel itraconazole formulation work intended to support pharmacokinetic studies and regulatory filings.
Exclusive patent rights and know-how licensed from Johns Hopkins University and related IP assets.
Asiakkaat
The company does not sell commercial products today; its end customers are patients and physicians in oncology and rare-disease settings if development succeeds. Near term, its direct counterparties are regulators, clinical collaborators, and research partners that support the IND/NDA pathway. The commercial opportunity is concentrated in patients with BCCNS and other cancers where itraconazole-based treatment could address unmet need.
Patients targeted by the lead itraconazole program for BCCNS-related tumors and basal cell carcinoma.
Future patient populations for the company's patent-protected oncology expansion programs.
FDA reviewers and divisions that determine whether the company can advance to IND, trial, and NDA stages.
External experts and Avior Bio supporting formulation, PK work, and regulatory preparation.
Strategia
The core strategy is to repurpose an already approved active ingredient into patent-protected oncology therapies, reducing scientific risk versus de novo drug discovery. Management is prioritizing the BCCNS program, FDA interaction, and formulation work needed to determine whether additional clinical trials are required before an NDA submission. The company also intends to license or acquire additional pre-clinical and clinical-stage assets that fit the same repurposing model.
Regulatory clarity determines whether the company needs more trials before NDA submission.
The formulation supports PK comparison and may strengthen the regulatory package.
Additional assets could diversify risk beyond the lead BCCNS program.
Maantiede
The company is headquartered in the United States and its development and regulatory work is centered there. Its patent rights are described as worldwide, but the current clinical and FDA pathway is U.S.-focused, making domestic regulatory execution the key geographic driver. Any eventual commercialization could expand beyond the U.S., but no operating revenue geography is disclosed.
Riskit
The company is highly dependent on FDA review outcomes, timing, and interpretation of its development package, which can materially delay or prevent commercialization. As a pre-revenue biotech, it also faces financing risk, clinical development uncertainty, and dependence on third-party partners for formulation and study execution. Broader sector risks include regulatory shutdowns, trial failure, patent challenges, and the possibility that repurposed itraconazole does not demonstrate sufficient efficacy or safety in the targeted indications.
- FDA review and regulatory timing riskVaikutus: KorkeaTodennäköisyys: Korkea
The business depends on timely FDA feedback and approval of the development path.
Kohdistuu - Need for additional clinical trialsVaikutus: KorkeaTodennäköisyys: Korkea
If the FDA requires more data, development costs and timelines could increase materially.
Kohdistuu: HP2001 and future BCCNS studies
- Financing and dilution riskVaikutus: KorkeaTodennäköisyys: Korkea
The company may need to raise capital to fund development and future opportunities.
Kohdistuu: Public market capital raises
- Regulatory shutdown / agency disruption riskVaikutus: KeskitasoTodennäköisyys: Korkea
Government shutdowns can delay FDA and SEC processing and access to capital markets.
Kohdistuu: FDA and SEC review processes
- Program concentration riskVaikutus: Keskitaso
Value is concentrated in a small number of repurposed oncology programs.
Kohdistuu
Kirjanpito
Harkinnanvaraiset erätClinical, formulation, and regulatory costs are expensed as incurred and drive operating losses.
Vaikutus: Affects quarterly burn rate and comparability across periods
Exclusive patent rights and licensed IP may need impairment testing if development stalls.
Vaikutus: Could create non-cash charges if expected value declines
Pre-commercial biotech reporting relies heavily on judgment due to limited operating history.
Vaikutus: Can affect accruals, provisions, and asset valuation
Any new partnering or licensing deals could introduce revenue recognition and milestone timing issues.
Vaikutus: Could change reported revenue and deferred income balances
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Context Therapeutics Inc.
CNTX · Pharmaceutical Preparations
Intensity Therapeutics, Inc
INTS · Biological Products, (No Diagnostic Substances)
Inhibikase Therapeutics, Inc.
IKT · Biological Products, (No Diagnostic Substances)
Indaptus Therapeutics, Inc.
INDP · Pharmaceutical Preparations
BriaCell Therapeutics Corp.
BCTXZ · Pharmaceutical Preparations
BridgeBio Oncology Therapeutics, Inc.
BBOT · Pharmaceutical Preparations
Päivitetty: 24.9.2026